Dermatological Abnormalities in Beta-thalassemia Major

Status Not yet recruiting

Clinical Trial Summary

to study the frequency and pattern of dermatological abnormalities in egyptian childern with beta thalassemia.relationof abnormalities to duration of disease and frequency of transfusion

Clinical Trial Description

thalassemia refers to agroup of inherited disease characterized by decreased or absent synthesis of normal globin .skinvdisorders are usually neglected and frequently underdiagnosed among these patients.skin disease specially pruritus and xerosis are observed highly frequently in patients with beta-thalassemia.pityriasis alba is arelatively common skin disorder.the trophic skin changes and leg ulcers occurred after the age of 15 years ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03894605
Study type	Observational
Source	Assiut University
Contact	Alsayed khalil Abd elkareem, Professor
Phone	01060805170
Email	Khalilsay@gmail.com
Status	Not yet recruiting
Phase
Start date	March 2, 2020
Completion date	April 2, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00069862` - Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia	Phase 1/Phase 2
Completed	`NCT00733811` - Efficacy Study of the Use of Sequential DFP-DFO Versus DFP	Phase 4
Completed	`NCT05506358` - Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada	N/A
Withdrawn	`NCT04938635` - Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia	Phase 2
Active, not recruiting	`NCT03655678` - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia	Phase 2/Phase 3
Completed	`NCT06239389` - Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.	Phase 2
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT03271541` - A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia	Phase 2
Terminated	`NCT02274233` - Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia	Phase 1
Completed	`NCT01206075` - Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major	N/A
Recruiting	`NCT05567458` - A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.	Phase 2
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Completed	`NCT03961828` - Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus	Phase 4
Recruiting	`NCT06065189` - Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major	Early Phase 1
Recruiting	`NCT04143724` - Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia	Phase 2
Terminated	`NCT03381833` - A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia	Phase 2
Completed	`NCT02268409` - ACE-536 Extension Study - Beta Thalassemia	Phase 2
Not yet recruiting	`NCT01996683` - Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)	N/A
Active, not recruiting	`NCT01016093` - Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients	Phase 2/Phase 3
Completed	`NCT01039636` - Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload	Phase 1